ACRV Acrivon Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1781174 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY9.6%
TTM EPS YoY14.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-74.1%
ROA-64.0%
ROIC (approx.)-104.8%
Asset turnover—
Leverage & solvency
Liabilities / assets17.5%
Debt / equity0.00x
Current ratio5.54x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $59.99M | $63.99M | $46.02M | $23.95M | — |
| SG&A expense | $24.12M | $25.21M | $21.08M | $8.71M | — |
| Operating income | -$84.11M | -$89.20M | -$67.10M | -$32.66M | -$16.18M |
| Pretax income | -$77.83M | -$80.44M | — | — | — |
| Income tax | $0 | — | — | — | — |
| Net income | -$77.91M | -$80.56M | -$60.39M | -$31.17M | -$16.24M |
| EBITDA | -$82.76M | -$88.19M | -$66.57M | -$32.29M | -$16.15M |
| EPS (basic) | -2.02 | -2.38 | -2.74 | -7.56 | -9.32 |
| EPS (diluted) | -2.02 | -2.38 | -2.74 | -7.56 | -9.32 |
| Weighted avg. shares (diluted) | 38.51M | 33.79M | 22.08M | 4.12M | 1.74M |
| Balance sheet | |||||
| Cash & equivalents | $41.50M | $39.82M | $36.02M | $29.52M | $99.60M |
| Short-term investments | $77.08M | $139.66M | $91.44M | $98.23M | — |
| Current assets | $120.44M | $181.63M | $129.69M | $132.09M | $100.41M |
| PP&E, net | $4.89M | $4.47M | $3.48M | $2.09M | $290,000 |
| Total assets | $129.72M | $196.59M | $138.26M | $181.23M | $106.59M |
| Current liabilities | $15.66M | $17.21M | $13.30M | $6.52M | $2.91M |
| Total liabilities | $17.20M | $19.80M | $17.07M | $10.75M | $7.88M |
| Shareholders' equity | $112.52M | $176.79M | $121.19M | $170.47M | -$23.81M |
| Shares outstanding | 31.65M | 31.23M | 22.52M | 21.92M | 1.77M |
| Cash flow statement | |||||
| Operating cash flow | -$63.66M | -$65.67M | -$42.64M | -$30.12M | -$13.98M |
| Capital expenditure | $1.67M | $2.77M | $1.29M | $2.17M | $238,000 |
| Free cash flow | -$65.33M | -$68.44M | -$43.93M | -$32.28M | -$14.22M |
| Investing cash flow | $66.10M | -$51.77M | $50.72M | -$141.68M | -$238,000 |
| Financing cash flow | -$749,000 | $121.03M | -$1.55M | $101.71M | $112.22M |
| Depreciation & amortization | $1.36M | $1.01M | $536,000 | $364,000 | $37,000 |
| Stock-based compensation | $14.72M | $14.29M | $11.62M | $2.19M | $497,000 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.